
Retina
Latest News

ONL Therapeutics secures financing to advance lead compound into Phase 2 clinical trial
Latest Videos
CME Content
More News

Despite its promise, RGC replacement represents a more formidable challenge.

Artificial intelligence (AI) with ultra-widefield fundus autofluorescence images may be helpful to objectively estimate progression of retinitis pigmentosa (RP) and visual function.

Yusuke Oshima, MD, PhD, in a presentation at the 38th Asia-Pacific Academy of Ophthalmology Congress, Kuala Lumpur, Malaysia, discussed the advantages of using a beveled-tip ultra-speed probe for complete vitreous shaving during retinal detachment vitrectomies.

Analysis of data from the pooled Tenaya and Lucerne studies showed the faricimab achieved greater anatomic improvements compared to aflibercept during the matched-dosing period.

Arun Singh, MD, discusses Retinoblastoma in 2023 and the advancements of tumor chemotherapy from his presentation at the Asia-Pacific Academy of Ophthalmology (APAO) 2023 conference.

The considerations for biosimilars in clinical practice are interesting and remain to be determined, according to George A. Williams, MD.

Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.

Carolyn Majcher, OD, FAAO, and Rishi Singh, MD, discuss new and upcoming clinical trials, investigational therapies, and diagnostic tools for the treatment of diabetic retinopathy and diabetic macular edema (DR/DME).

Diabetic retinal disease experts discuss different approaches that can reduce the treatment burden while maintaining good visual outcomes during diabetic retinopathy and diabetic macular edema (DR/DME) therapy.

Rishi Singh, MD, provides an overview of the various treatment options available for diabetic retinopathy and diabetic macular edema (DR/DME).

The company announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.

Three of Frontera’s gene therapy product candidates have entered clinical trials since the beginning of the year.

According to a news release, Akari is targeting an Investigational New Drug application submission to the FDA in the first half of 2024.

The collaboration may provide insights to help improve the treatment paradigm for retinal disorders.

The survey addressed topics that would facilitate a better understanding of the awareness of retina specialists regarding this relative new form of treatment in ophthalmology.

Sharing data between ophthalmologists, optometrists can lead to earlier diagnosis

The findings from a National Institutes of Health-supported clinical trial may help guide the management of diabetic eye disease.

Bonnie An Henderson, MD, founder and program director of EnVision Summit, previews what attendees can expect at this year’s meeting - from its diverse faculty to an inclusive Youth Program, while also giving back to the community. The conference will take place February 17 to 20 at the El Conquistador Resort in Fajardo, Puerto Rico.

Rishi Singh, MD, provides an overview of the stages of diabetic retinopathy and diabetic macular edema (DR/DME) and the retinal findings associated with each stage as well as factors to consider when selecting therapy.

Carolyn Majcher, OD, FAAO, discusses when to refer patients with diabetic retinopathy and diabetic macular edema (DR/DME) to a retina specialist.

Roche announced that faricimab met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared to aflibercept.

The approval of aflibercept for preterm infants with retinopathy of prematurity (ROP) expands the treatment armamentarium for these patients, comments Prof Anat Loewenstein.

According to Regeneron, aflibercept injection is now approved to treat five retinal conditions caused by ocular angiogenesis.

According to the company, EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into photoreceptors and can potentially preserve or restore visual function.

According to investigators, a new proposed classification for large and extra-large full-thickness macular holes is based on the surgical results achieved with different surgical techniques






























